What are the efficacy and functions of ivonib? What types of cancer are treated?

Ivosidenib is a targeted anticancer drug mainly used to treat cancers carrying IDH1 mutations. It is an IDH1 (isocitrate dehydrogenase 1) inhibitor that blocks the activity of IDH1 mutant enzyme and reduces the accumulation of the metabolite D-2-hydroxyglutarate (D-2-HG) in tumor cells, thereby inhibiting the growth and spread of cancer cells. This mechanism of action makes ivonib a precision treatment drug for cancers with specific genetic mutations.

Ivonib was first approved for the treatment of relapsed or refractory acute myeloid leukemia (AML) and is suitable for adult patients carrying IDH1 mutations. For such patients, ivonib can effectively inhibit the abnormal metabolism of leukemia cells and help restore normal hematopoietic function, thus improving the disease control rate. In addition, it is also suitable for newly diagnosed AML patients who are not suitable for standard chemotherapy. As a single-agent treatment option, it provides a milder treatment option and reduces the toxic and side effects caused by traditional chemotherapy.

In addition to AML, ivosidenib is also used to treat cholangiocarcinoma, especially locally advanced or metastatic cholangiocarcinoma harboring IDH1 mutations. In this cancer type, IDH1 mutations lead to abnormal proliferation of cholangiocytes, and the inhibitory effect of ivonib can reduce cancer cell metabolism disorders and slow tumor progression. Research shows that ivonib can prolong progression-free survival (PFS) and provide a new treatment option for patients with advanced cholangiocarcinoma, especially those who are ineffective or poorly tolerated by standard chemotherapy.
Overall, the main indications for ivonib are AML and cholangiocarcinoma carrying IDH1 mutations, but with the deepening of research, its potential in other IDH1 mutation-related cancers (such as glioma, etc.) is also being explored. Due to its precise targeting of IDH1 mutations, the treatment effect is significant in specific patient groups, and the side effects are relatively controllable. However, before use, patients must undergo genetic testing to confirm whether they carry IDH1 mutations to ensure the accuracy and effectiveness of treatment.
Reference link: https://www.tibsovo.com/